LCI699 clinical trials

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

This study looks at a new medicine called osilodrostat (LCI699) for children and teenagers aged 2-17 with Cushing's syndrome. Researchers want to see how the medicine works in the body, its effects, and if it's safe. It's for those who have had surgery, are waiting for it, or can't have it right away.